Eli Lilly and Company (LLY) Stock Forecast & Price Target

$1,184.38 +2.49 (+0.21%)

Closing price 09/25/2026 03:59 PM Eastern

Extended Trading

$1,183.80 -0.58 (-0.05%)

As of 09/25/2026 07:59 PM Eastern

Compare

Eli Lilly and Company - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 30 Analyst Ratings

Sell
1

Hold
3

Buy
26

Based on 30 Wall Street analysts who have issued ratings for Eli Lilly and Company in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 30 analysts, 1 has given a sell rating, 3 have given a hold rating, 25 have given a buy rating, and 1 has given a strong buy rating for LLY.

Consensus Price Target

$1,308.39
10.47% Upside

According to the 30 analysts' twelve-month price targets for Eli Lilly and Company, the average price target is $1,308.39. The highest price target for LLY is $1,600.00, while the lowest price target for LLY is $900.00. The average price target represents a forecasted upside of 10.47% from the current price of $1,184.38.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for LLY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Eli Lilly and Company and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LLY Analyst Ratings Over Time

Type	Current Forecast 9/26/25 to 9/26/26	1 Month Ago 8/27/25 to 8/27/26	3 Months Ago 6/28/25 to 6/28/26	1 Year Ago 9/26/24 to 9/26/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	25 Buy rating(s)	24 Buy rating(s)	23 Buy rating(s)	14 Buy rating(s)
Hold	3 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	6 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$1,308.39	$1,292.18	$1,235.07	$939.61
Forecasted Upside	10.47% Upside	9.97% Upside	2.37% Upside	29.65% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

LLY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

LLY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Eli Lilly and Company Stock vs. The Competition

Type	Eli Lilly and Company	Healthcare Companies	Broader Market
Consensus Rating Score	2.87	2.31	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	10.47% Upside	764.10% Upside	19.20% Upside
News Sentiment Rating	Neutral News See Recent LLY News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/22/2026	TD Cowen 3 of 5 stars	Steve Scala Not Rated	Reiterated Rating	Buy	$1,250.00	+7.24%
9/18/2026	Guggenheim 5 of 5 stars	Seamus Fernandez 5 of 5 stars	Boost Target	Buy	$1,273.00 ➝ $1,284.00	+11.45%
9/17/2026	The Goldman Sachs Group 3 of 5 stars		Boost Target	Buy	$1,367.00 ➝ $1,371.00	+18.84%
9/15/2026	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kerry Holford Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Hold ➝ Buy	$1,400.00	+22.92%
9/10/2026	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rajesh Kumar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Reduce	$850.00 ➝ $940.00	-16.33%
9/9/2026	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Evan David Seigerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform
8/26/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Buy (B-) ➝ Buy (B)
8/7/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Yee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$1,376.00	+16.86%
8/7/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robyn Karnauskas Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$1,370.00 ➝ $1,376.00	+16.57%
8/6/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Terence Flynn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$1,419.00	+21.25%
A letter from Shannon Stansberry (Ad) Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. Watch the full story and see the verified track record for yourself
8/6/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$1,280.00 ➝ $1,330.00	+13.65%
8/6/2026	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Carter Gould Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$1,350.00 ➝ $1,410.00	+20.48%
7/15/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Geoff Meacham Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$1,500.00 ➝ $1,600.00	+38.62%
7/14/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Courtney Breen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$1,300.00 ➝ $1,385.00	+20.98%
7/10/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jason Gerberry Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$1,251.00 ➝ $1,334.00	+12.69%
7/8/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Trung Huynh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$1,250.00 ➝ $1,500.00	+23.00%
7/7/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Chris Schott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$1,300.00 ➝ $1,400.00	+16.58%
6/25/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Risinger Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$1,119.00 ➝ $1,232.00	+10.40%
6/9/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Akash Tewari Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$1,330.00 ➝ $1,350.00	+18.19%
5/21/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alexandria Hammond Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$1,350.00	+30.12%
5/7/2026	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target		$880.00 ➝ $900.00	-7.27%
5/4/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Emily Field Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$1,350.00 ➝ $1,400.00	+44.62%
3/6/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	James Shin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$1,285.00	+30.49%
2/18/2026	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Narumi Nakagiri Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$1,230.00 ➝ $1,250.00	+22.24%
2/11/2026	CICC Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Neutral	$1,060.00 ➝ $1,107.00	+5.53%
2/10/2026	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ilya Zubkov Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$1,200.00	+17.07%
2/10/2026	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy
2/9/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$930.00 ➝ $1,200.00	+14.40%
2/5/2026	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform	$1,300.00	+26.01%
1/30/2026	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
12/1/2025	National Bank Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tim Anderson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$1,286.00	+21.58%
10/14/2025	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Buy
8/14/2025	DZ Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 04:50 PM ET.

Should I Buy Eli Lilly and Company Stock? LLY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 23, 2026. Please send any questions or comments about these Eli Lilly and Company pros and cons to contact@marketbeat.com.

Eli Lilly and Company
Bull Case

Here are some ways that investors could benefit from investing in Eli Lilly and Co:

Eli Lilly and Co is currently trading at $1,153.69, a level that remains well below the average analyst price target of $1,305.25, suggesting significant upside potential as the stock trades at a price-to-earnings ratio of 38.71 which is supported by strong earnings growth.
The company demonstrated exceptional commercial momentum by capturing approximately 70% of new senior GLP-1 patients following the expansion of Medicare coverage, a development that materially enlarges the addressable market and reinforces its leadership in the obesity treatment sector.
Recent financial results show robust performance, with the company reporting $8.38 in earnings per share for the most recent quarter, significantly topping the consensus estimate of $6.40, while revenue grew 47.7% year-over-year to $22.97 billion, indicating strong demand for its products.
Investors can benefit from the company's strategic expansion into domestic manufacturing, as Eli Lilly and Co broke ground on a $6.5 billion facility in Houston that will produce active ingredients for its oral GLP-1 drug Foundayo, strengthening supply chains and supporting long-term growth.
The stock exhibits lower volatility compared to the broader market with a beta of 0.50, and institutional investors continue to show confidence, with 82.53% of the stock owned by institutions and recent purchases by major funds like BlackRock and State Street.

Eli Lilly and Company
Bear Case

Investors should be bearish about investing in Eli Lilly and Co for these reasons:

Competitive pressure is intensifying as Viking Therapeutics reported data for its VK2735 obesity drug showing it preserves most weight loss with less frequent dosing, which could threaten Eli Lilly and Co's market share and pricing power in the future.
The company faces significant capital expenditure requirements, including the $6.5 billion investment in the new Houston manufacturing facility, which may temper near-term enthusiasm and impact cash flow despite the long-term benefits of increased production capacity.
Insider selling activity has been notable recently, with executives such as EVP Anat Hakim and CAO Donald Zakrowski selling a combined 7,000 shares in August 2026, which some investors may interpret as a signal of limited near-term upside or personal financial planning needs.
Novo Nordisk continues to pose a strong competitive threat, with its CagriSema drug producing favorable late-stage weight-loss data, keeping competitive pressure high and potentially limiting Eli Lilly and Co's ability to maintain its current premium valuation.
The stock has experienced recent price declines, dropping $16.45 to $1,153.69 on September 23, 2026, and trading below its 50-day moving average of $1,176.84, indicating short-term bearish momentum and potential technical weakness.

LLY Forecast - Frequently Asked Questions

According to the research reports of 30 Wall Street equities research analysts, the average twelve-month stock price forecast for Eli Lilly and Company is $1,308.39, with a high forecast of $1,600.00 and a low forecast of $900.00.

30 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and Company in the last year. There is currently 1 sell rating, 3 hold ratings, 25 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LLY shares.

According to analysts, Eli Lilly and Company's stock has a predicted upside of 10.47% based on their 12-month stock forecasts.

Over the previous 90 days, Eli Lilly and Company's stock had 4 upgrades and 1 downgrade by analysts.

Eli Lilly and Company has been rated by research analysts at Bank of America, Berenberg Bank, BMO Capital Markets, Cantor Fitzgerald, Citigroup, Guggenheim, HSBC, JPMorgan Chase & Co., Morgan Stanley, Royal Bank Of Canada, Sanford C. Bernstein, TD Cowen, The Goldman Sachs Group, Truist Financial, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Eli Lilly and Company more than other "healthcare" companies. The consensus rating for Eli Lilly and Company is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how LLY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Eli Lilly and Company Recommendations

MarketBeat monitors more than a dozen sources for Eli Lilly and Company analyst ratings, with the most recent rating issued on 9/22/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eli Lilly and Company (LLY) Stock Forecast & Price Target